Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 15
Phase 217

Trial Status

Completed22

Role Distribution

Principal Investigator22
PI Rate100%

Activity Timeline

Clinical Trials (20)

NCT00000219Phase 1Completed
Buprenorphine Dose Alteration Study - 1
Opioid-Related Disorders
Principalinvestigator
NCT00000220Phase 1Completed
Gradual Vs. Rapid Buprenorphine Detoxification - 2
Opioid-Related Disorders
Principalinvestigator
NCT00000221Phase 1Completed
Alternate-Day Buprenorphine Administration. Phase I - 3
Opioid-Related Disorders
Principalinvestigator
NCT00000222Phase 1Completed
Alternate-Day Buprenorphine Administration. Phase II - 4
Opioid-Related Disorders
Principalinvestigator
NCT00000223Phase 2Completed
Alternate-Day Buprenorphine Administration. Phase IV - 5
Opioid-Related Disorders
Principalinvestigator
NCT00000224Phase 1Completed
Alternate-Day Buprenorphine. Phase V - 6
Opioid-Related Disorders
Principalinvestigator
NCT00000225Phase 2Completed
Alternate-Day Buprenorphine Administration. Phase VI - 7
Opioid-Related Disorders
Principalinvestigator
NCT00000226Phase 2Completed
Alternate-Day Buprenorphine Administration. Phase VII - 8
Opioid-Related Disorders
Principalinvestigator
NCT00000227Phase 2Completed
Alternate-Day Buprenorphine Administration. Phase VIII - 9
Opioid-Related Disorders
Principalinvestigator
NCT00000228Phase 2Completed
Buprenorphine Detox With Two Types of Treatment. BBD I - 10
Opioid-Related Disorders
Principalinvestigator

Showing 10 of 20 trials

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

University of Vermont

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Eugene Somoza, M.D., Ph.D.

Cincinnati MDRU

Moderately Similar
7 trials

Shared therapeutic areas:

Cocaine-Related DisordersOpioid-Related Disorders

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score30%

Walter Ling, M.D.

Friends Research Institute, Inc.

Moderately Similar
28 trials

Shared therapeutic areas:

Opioid-Related DisordersCocaine-Related Disorders

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score30%

Mark Greenwald, PhD

Wayne State University

Moderately Similar
15 trials

Shared therapeutic areas:

Opioid-Related DisordersCocaine-Related Disorders

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score30%

Eric C. Strain, MD

Johns Hopkins University

Moderately Similar
9 trials

Shared therapeutic areas:

Opioid-Related DisordersCocaine-Related Disorders

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score30%

Kenneth Silverman, Ph.D.

Johns Hopkins University

Moderately Similar
8 trials

Shared therapeutic areas:

Opioid-Related DisordersCocaine-Related Disorders

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score30%

Kenzie Preston, Ph.D.

National Institute on Drug Abuse (NIDA)

Moderately Similar
9 trials

Shared therapeutic areas:

Opioid-Related DisordersCocaine-Related Disorders

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score30%

Thomas R Kosten, M.D.

VA Connecticut Healthcare System

Moderately Similar
10 trials

Shared therapeutic areas:

Cocaine-Related DisordersOpioid-Related Disorders

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score30%

Herbert Kleber, M.D.

New York State Psychiatric Institute

Moderately Similar
9 trials

Shared therapeutic areas:

Cocaine-Related DisordersOpioid-Related Disorders

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score30%

Charles O'Brien, M.D., Ph.D.

PDVAMC Treatment Research Center

Related
7 trials

Shared therapeutic areas:

Opioid-Related Disorders

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score15%

Elizabeth Ralevski, Ph.D.

Yale University

Related
6 trials

Shared therapeutic areas:

Opioid-Related Disorders
Similarity Score15%

Publications (0)

No publications found for this investigator.

Clinical Trials (22)

Showing 20 of 22 trials

NCT00000219Phase 1PrincipalInvestigator

Buprenorphine Dose Alteration Study - 1

Opioid-Related Disorders
Completed
NCT00000220Phase 1PrincipalInvestigator

Gradual Vs. Rapid Buprenorphine Detoxification - 2

Opioid-Related Disorders
Completed
NCT00000221Phase 1PrincipalInvestigator

Alternate-Day Buprenorphine Administration. Phase I - 3

Opioid-Related Disorders
Completed
NCT00000222Phase 1PrincipalInvestigator

Alternate-Day Buprenorphine Administration. Phase II - 4

Opioid-Related Disorders
Completed
NCT00000223Phase 2PrincipalInvestigator

Alternate-Day Buprenorphine Administration. Phase IV - 5

Opioid-Related Disorders
Completed
NCT00000224Phase 1PrincipalInvestigator

Alternate-Day Buprenorphine. Phase V - 6

Opioid-Related Disorders
Completed
NCT00000225Phase 2PrincipalInvestigator

Alternate-Day Buprenorphine Administration. Phase VI - 7

Opioid-Related Disorders
Completed
NCT00000226Phase 2PrincipalInvestigator

Alternate-Day Buprenorphine Administration. Phase VII - 8

Opioid-Related Disorders
Completed
NCT00000227Phase 2PrincipalInvestigator

Alternate-Day Buprenorphine Administration. Phase VIII - 9

Opioid-Related Disorders
Completed
NCT00000228Phase 2PrincipalInvestigator

Buprenorphine Detox With Two Types of Treatment. BBD I - 10

Opioid-Related Disorders
Completed
NCT00000229Phase 2PrincipalInvestigator

Buprenorphine Detox With Two Types of Treatment. BBD II - 11

Opioid-Related Disorders
Completed
NCT00000230Phase 2PrincipalInvestigator

Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12

Opioid-Related Disorders
Completed
NCT00000231Phase 2PrincipalInvestigator

Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13

Opioid-Related Disorders
Completed
NCT00000232Phase 2PrincipalInvestigator

Alternate Day Buprenorphine Administration, Phase IX - 14

Opioid-Related Disorders
Completed
NCT00000233Phase 2PrincipalInvestigator

Alternate Day Buprenorphine Administration, Phase X - 15

Opioid-Related Disorders
Completed
NCT00000234Phase 2PrincipalInvestigator

Alternate Day Buprenorphine Administration, Phase XI - 16

Opioid-Related Disorders
Completed
NCT00000235Phase 2PrincipalInvestigator

Alternate Day Buprenorphine Administration, Phase XII - 17

Opioid-Related Disorders
Completed
NCT00000236Phase 2PrincipalInvestigator

Buprenorphine Pharmacology Related to Addiction Treatment - 18

Opioid-Related Disorders
Completed
NCT00000237Phase 2PrincipalInvestigator

Buprenorphine Detoxification - BBDVI - 19

Opioid-Related Disorders
Completed
NCT00000238Phase 2PrincipalInvestigator

Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20

Opioid-Related Disorders
Completed